GBI Research
ReportStore
 

 
Browse the latest press releases.
 
 

Media Center

 
 

256 Press Releases

Page 1 of 11
Thanks to patent expirations of several key therapies, the Human Immunodeficiency Virus (HIV) treatment market value will increase at a slow pace in the coming years, from $14.3 billion in 2012 to $16.3 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 1.9%.
Published: 15-Apr-2014
Separator
As the prevalence of diabetes continues to expand rapidly across the world, the insulin delivery devices market value is expected to increase from $8.78 billion in 2012 to $13.8 billion by 2019, at a significant Compound Annual Growth Rate (CAGR) of 7%.
Published: 10-Apr-2014
Separator
Despite the elderly being the fastest-growing segment of the global population, only a few of their treatments have been clinically trialed in age-appropriate patients, with many of their therapies still not available in suitable formulations and dosages.
Published: 08-Apr-2014
Separator
The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region — Australia, China, India and Japan — is expected to increase moderately over the coming years, climbing from $1.8 billion in 2012 to $2.9 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 6.3%.
Published: 18-Mar-2014
Separator
The epilepsy therapeutics market value in the eight major countries — the US, Canada, France, Germany, Italy, Spain, the UK and Japan — will increase from $3.4 billion in 2012 to $4.5 billion by 2019, at a modest Compound Annual Growth Rate (CAGR) of 3.9%.
Published: 12-Mar-2014
Separator
The global Cystic Fibrosis (CF) market value in the seven major countries (7MM: the US, Canada, France, Germany, Italy, Spain and the UK) will jump from $1.2 billion in 2013 to just under $4.5 billion by 2019, at a massive Compound Annual Growth Rate (CAGR) of 30.4%.
Published: 11-Mar-2014
Separator
The epilepsy therapeutics market value in the Asia-Pacific (APAC) region — Australia, China, India and Japan — is expected to increase moderately, climbing from $1.1 billion in 2012 to $1.5 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 4.7%.
Published: 27-Feb-2014
Separator
While the Systemic Lupus Erythematosus (SLE) treatment market is predominantly limited to Benlysta and off-label Rituxan, new emerging entrants, which appear to offer significant therapeutic benefits, will cause dramatic changes to the future SLE biological treatment market landscape.
Published: 18-Feb-2014
Separator
The systemic psoriasis treatment market value in the eight major countries (8MM) — the US, Canada, France, Germany, Italy, Spain, the UK and Japan — is expected to more than double in the near future, jumping from $5 billion in 2013 to $10.4 billion by 2020, at a significant Compound Annual Growth Rate (CAGR) of 11.1%.
Published: 04-Feb-2014
Separator
Due to a large untreated patient pool and the recent approval of new treatments, the hepatitis C market will more than treble from $5.7 billion in 2012 to $18.6 billion by 2019, at an impressive Compound Annual Growth Rate (CAGR) of 18.5%.
Published: 30-Jan-2014
Separator
The global glucose monitoring devices market value will experience a moderate increase from $9.9 billion in 2012 to $13.7 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5%.
Published: 28-Jan-2014
Separator
The gastrointestinal (GI) therapeutics market for Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD) in the Asia-Pacific (APAC) region will increase in value from $564m in 2012 to $784m by 2019, at a Compound Annual Growth Rate (CAGR) of 4.8%.
Published: 28-Jan-2014
Separator
The global market for traditional wound management will climb from $1.6 billion in 2012 to $1.9 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 2.1%, as the therapy continues to be the primary mode of treatment in developing countries.
Published: 22-Jan-2014
Separator
Due to favorable market conditions in terms of US pricing structures and the anticipated approval of a number of late-stage pipeline drugs, the market value for monoclonal antibodies (mAbs) in gastric and esophageal cancer treatment is expected to double by 2019.
Published: 17-Jan-2014
Separator
The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis (UC), and Crohn’s disease (CD) in the eight major markets (8MM) — the US, UK, France, Germany, Italy, Spain, Canada and Japan — is expected to decrease in value from $6.8 billion in 2012 to $6.6 billion by 2019, at a negative Compound Annual Growth Rate (CAGR) of 0.3%.
Published: 15-Jan-2014
Separator
Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s Disease (PD) market is expected to decline from $3.4 billion in 2012 to $2.9 billion by 2019, at a negative Compound Annual Growth Rate (CAGR) of 2.3%.
Published: 17-Dec-2013
Separator
The market value for monoclonal antibodies (mAbs) in colorectal cancer treatment will experience a moderate increase from $3.7 billion in 2012 to $5.2 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5%.
Published: 13-Dec-2013
Separator
The ophthalmology therapeutics market for Dry Eye Syndrome (DES) and glaucoma in the eight major countries — the US, the UK, France, Germany, Italy, Spain, Canada and Japan — is expected to increase moderately, climbing from $3.7 billion in 2012 to $6.1 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 7.6%.
Published: 11-Dec-2013
Separator
The global market for Cardiovascular Disease (CVD) — comprised of Heart Failure (HF), Myocardial Infarction and Acute Coronary Syndrome (ACS) — is expected to grow at a moderate rate, from $13.7 billion in 2012 to $18.2 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 4.1%.
Published: 02-Dec-2013
Separator
The ophthalmology therapeutics market for Dry Eye Syndrome (DES) and glaucoma in four Asia-Pacific (APAC) countries — India, Australia, China and Japan — will increase from $2.4 billion in 2012 to $3.3 billion in 2019, at a Compound Annual Growth Rate (CAGR) of 5%.
Published: 22-Nov-2013
Separator
The growing prevalence of pressure ulcers will boost the pressure relief devices market, which is expected to increase from $2.9 billion in 2012 to $4.1 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 4.7%.
Published: 21-Nov-2013
Separator
Due to the growing prevalence of prostate cancer and the launch of new products for the condition, the prostate cancer treatment market will increase from $4.1 billion in 2012 to $8 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 10.1%.
Published: 20-Nov-2013
Separator
As a result of Phase III therapy LMTX potentially entering the Alzheimer’s Disease (AD) industry in the near future, the AD market will increase slightly from $3.6 billion in 2012 to $3.8 billion in 2019.
Published: 07-Nov-2013
Separator
The market value for monoclonal antibodies (mAbs) in breast cancer treatment will experience a massive increase from $4.8 billion in 2012 to $10.9 billion in 2019, demonstrating a Compound Annual Growth Rate (CAGR) of 12.2%.
Published: 06-Nov-2013
Separator
Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration market in the Asia-Pacific region (India, Australia, China and Japan) is expected to undergo a moderate increase from $675.7m in 2012 to $1,016.1m by 2019, at a Compound Annual Growth Rate (CAGR) of 6%.
Published: 29-Oct-2013